Jason Hoitt
Corporate Officer/Principal presso STOKE THERAPEUTICS, INC.
Profilo
Jason Hoitt is currently the Chief Commercial Officer at Stoke Therapeutics, Inc. He previously held positions as the Head-US Sales at Sarepta Therapeutics, Inc. from 2013 to 2017, Vice President & Head-US Sales at Insmed, Inc. in 2017 to 2018, Chief Commercial Officer at Dova Pharmaceuticals, Inc. from 2018 to 2019, and Chief Commercial Officer at Provention Bio, Inc. from 2020 to 2023.
Mr. Hoitt obtained his undergraduate degree from the College of the Holy Cross (Massachusetts) in 1999.
Posizioni attive di Jason Hoitt
| Società | Posizione | Inizio |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 15/04/2024 |
Precedenti posizioni note di Jason Hoitt
| Società | Posizione | Fine |
|---|---|---|
| PROVENTION BIO, INC. | Corporate Officer/Principal | 01/06/2023 |
| DOVA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 12/11/2019 |
| INSMED INCORPORATED | Sales & Marketing | - |
| SAREPTA THERAPEUTICS, INC. | Sales & Marketing | 01/05/2017 |
Formazione di Jason Hoitt
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| INSMED INCORPORATED | Health Technology |
| STOKE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Borsa valori
- Insiders
- Jason Hoitt
